Sentinel Oncology

Sentinel Oncology, established in 2005 in Cambridge, UK, is a drug discovery company dedicated to the development and commercialization of novel therapies to treat patients with currently unmet medical needs.The Sentinel Oncology portfolio includes a lead program licensed to Seattle Genetics Inc. and a second program at the drug candidate stage. We continue to develop a range of novel small molecules that enhance the therapeutic index by delivering their effects directly to tumors.Sentinel Oncology is a fully integrated drug discovery company committed to developing high-quality drugs and collaborating with pharmaceutical and biotechnology sectors. Our business model is collaborative, working with organizations that can maximize the value of our programs.